Shipwaves Online Ltd reported a 68.45% decline in FY26 net profit to Rs 384.87 lakh on lower revenues. Alongside these results, the company announced a preferential issue of 3.33 crore convertible warrants at Rs 4.50 each to raise Rs 14.99 crore for working capital.
Shipwaves Online Ltd FY26 Financial Results and Fundraising
Revenue from Operations: Rs 9,116.72 lakh | Profit After Tax: Rs 384.87 lakh
Reader Takeaway: Revenue and profits fell sharply in FY26, but the company is raising capital through preferential warrants to bolster liquidity.
What just happened
Shipwaves Online Ltd has released its financial results for the fiscal year ended March 31, 2026, showing a significant downturn in performance. Consolidated revenue fell by 15.81% to Rs 9,116.72 lakh, while net profit dropped 68.45% to Rs 384.87 lakh. The Board has also proposed a preferential issuance of 3,33,20,000 convertible warrants at a price of Rs 4.50 per warrant, totaling Rs 14.99 crore. The primary allottee is Mukka Proteins Limited, which is set to receive 2,93,20,000 warrants.
Why this matters
The capital raise is intended to support the company’s working capital requirements as it navigates a challenging business environment. Shareholders will vote on these proposals at the upcoming 11th Annual General Meeting scheduled for September 30, 2026. The shift in earnings performance underscores the operational pressures currently facing the firm's logistics and digital supply chain model.
Corporate Governance
During the audit process for FY26, the company noted two administrative delays in regulatory filings. Specifically, there was a 14-day delay in filing the investor grievance report and an 11-day delay in the Monitoring Agency Report. The company has already paid the required penalty of Rs 16,520 to the BSE for the grievance filing delay and clarified that the second instance was due to an interpretation variance regarding SME listing norms.
What to track next
Investors should monitor the AGM on September 30, 2026, to assess management's plan for operational recovery. Future updates on the deployment of the Rs 14.99 crore capital infusion will be critical for gauging how the company aims to improve its bottom-line performance in the coming quarters.
